(Q34810756)

4 August 2017

1 reference

title

Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations (English)

1 reference

4 August 2017

0 references

Andrew D Jacobs

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

95

1 reference

4 August 2017

issue

4 Suppl

1 reference

4 August 2017

page(s)

923-927

1 reference

4 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10756

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10756

Diffuse alveolar damage in a patient treated with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10756

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10756

Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10756

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10756

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.10756

1 reference

4 August 2017

1 reference